Promising immunotherapeutic approaches for primary effusion lymphoma.
Jutatip PanaamponSeiji OkadaPublished in: Exploration of targeted anti-tumor therapy (2024)
Primary effusion lymphoma (PEL) is a large B-cell neoplasm usually presenting as a serious effusion in body cavities without detectable tumor masses. It is an AIDS-related non-Hodgkin's lymphoma (HL) with human herpes virus 8 (HHV8)/Kaposi sarcoma-associated herpes virus (KSHV) infection. A combination antiretroviral therapy (cART) prolongs the lifespan of AIDS and AIDS-related malignant lymphoma patients, but PEL continues to have a dismal prognosis. PEL showed disappointing outcomes with standard chemotherapy such as CHOP or CHOP-like regimens. A PEL status highlights the urgent need for new therapeutic approaches and treatment strategies and improve clinical outcomes. This review discusses the current knowledge and some recent clinical trials for PEL in the platform of immunotherapy as well as promising future immunotherapeutic approaches for PEL.
Keyphrases
- diffuse large b cell lymphoma
- antiretroviral therapy
- hiv infected
- clinical trial
- human immunodeficiency virus
- hiv positive
- end stage renal disease
- hiv infected patients
- hiv aids
- endothelial cells
- healthcare
- newly diagnosed
- ejection fraction
- prognostic factors
- peritoneal dialysis
- magnetic resonance
- radiation therapy
- skeletal muscle
- randomized controlled trial
- metabolic syndrome
- low grade
- squamous cell carcinoma
- computed tomography
- adipose tissue
- high grade
- ultrasound guided
- single cell
- south africa
- men who have sex with men
- open label
- drug induced
- phase ii